Westfield Capital Management Co. LP Boosts Stake in Cencora, Inc. $COR

Westfield Capital Management Co. LP raised its position in shares of Cencora, Inc. (NYSE:COR) by 21.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 325,660 shares of the company’s stock after buying an additional 56,908 shares during the quarter. Westfield Capital Management Co. LP owned about 0.17% of Cencora worth $101,779,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Cencora by 4.1% during the third quarter. Vanguard Group Inc. now owns 23,395,547 shares of the company’s stock valued at $7,311,810,000 after purchasing an additional 916,506 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Cencora by 6.3% during the 2nd quarter. Geode Capital Management LLC now owns 4,787,609 shares of the company’s stock valued at $1,429,772,000 after buying an additional 284,229 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Cencora by 21.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,677,797 shares of the company’s stock valued at $1,461,965,000 after acquiring an additional 821,098 shares during the last quarter. Norges Bank bought a new position in shares of Cencora in the 2nd quarter valued at about $695,215,000. Finally, Viking Global Investors LP grew its position in Cencora by 95.0% in the second quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock worth $624,207,000 after acquiring an additional 1,013,913 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Cencora Stock Down 0.4%

Shares of COR opened at $363.08 on Thursday. The firm has a fifty day moving average price of $350.59 and a 200-day moving average price of $332.78. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. The firm has a market capitalization of $70.63 billion, a P/E ratio of 43.64, a P/E/G ratio of 1.70 and a beta of 0.68. Cencora, Inc. has a 12-month low of $248.11 and a 12-month high of $377.54.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, topping the consensus estimate of $4.04 by $0.04. The company had revenue of $85.93 billion for the quarter, compared to the consensus estimate of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The firm’s revenue was up 5.5% compared to the same quarter last year. During the same quarter last year, the firm posted $3.73 EPS. Equities research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be paid a dividend of $0.60 per share. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, February 13th. Cencora’s payout ratio is currently 28.85%.

Insider Activity at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,677 shares of the company’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the sale, the executive vice president directly owned 18,796 shares in the company, valued at approximately $6,484,620. This represents a 8.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the stock in a transaction on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the transaction, the executive vice president directly owned 23,891 shares in the company, valued at $8,173,111.10. The trade was a 12.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 15,220 shares of company stock worth $5,282,867. Company insiders own 0.38% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on COR shares. Wells Fargo & Company raised their price objective on Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Weiss Ratings upgraded Cencora from a “hold (c+)” rating to a “buy (b)” rating in a report on Thursday, February 5th. Jefferies Financial Group raised shares of Cencora from an “underperform” rating to a “buy” rating in a research note on Thursday, January 22nd. Robert W. Baird set a $415.00 price objective on shares of Cencora in a research report on Tuesday, January 13th. Finally, Bank of America lowered their target price on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a report on Monday, January 5th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $399.00.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.